Comparative in vitro activity and killing effect of trovafloxacin, DU-6859a, levofloxacin and sparfloxacin against Staphylococcus aureus. Focus on methicillin-resistant isolates

Clinical Drug Investigation

Volumn 14, Issue 4, 1997, Pages 330-336

  Giamarellos Bourboulis, E J ^a   Grecka, P ^a   Galani, I ^a   Giamarellou, H ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; SITAFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0030723853     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714040-00013     Document Type: Article

References (20)

1. Goldstein FW, Acar JF. Epidemiology of quinolone resistance: Europe and North and South America. Drugs 1995; 49 Suppl. 2: 36-42
2. Giamarellou H. Activity of quinolones against Gram-positive cocci: clinical features. Drugs 1995; 49 Suppl. 2: 58-66
3. Eliopoulos GM. In vitro activity of fluoroquinolones against Gram-positive bacteria. Drugs 1995; 49 Suppl. 2: 48-57
4. Coque TM, Singh KY, Murray BE. Comparative in vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci. J Antimicrob Chemother 1996; 37 (5): 1011-6
5. Korten V, Tomayako JF, Murray BE. Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against Gram-positive cocci. Antimicrob Agents Chemother 1994; 38 (3): 611-5
6. Nakane T, Iyobe S, Sato K, et al. In vitro antibacterial activity of DU-6859a, a new fluoroquinolone. Antimicrob Agents Chemother 1995; 39 (12): 2822-6
7. Patel JA, Pachucki CT, Lentino JR. Synergy of levofloxacin (L-ofloxacin) and oxacillin against quinolone-resistant Staphylococcus aureus measured by the time-kill method. Antimicrob Agents Chemother 1993; 37 (2): 339-41
8. Baquero F, Canton R. In vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. J Antimicrob Chemother 1996; 37 Suppl. A: 1-18
9. Hindler J. Tests to detect oxacillin (methicillin)-resistant staphylococci with an oxacillin screen plate. In: Isenberg HD, editor. Clinical microbiology procedures handbook. Washington DC: American Society for Microbiology 1992; 5.5. 1-7
10. Archer GL, Pennell E. Detection of methicillin resistance in staphylococci by using a DNA probe. Antimicrob Agents Chemother 1990; 34 (9): 1720-4
11. Woods GL, Washington JA. Antibacterial susceptibility tests: dilution and disk diffusion methods. In: Murray PR, Baron EJ, Pfaller MA, et al, editors. Manual of clinical microbiology. 6th ed. Washington DC: American Society for Microbiology, 1995; 1327-41
12. Teng R, Harris SC, Nix DE, et al. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother 1995; 36 (2): 385-94
13. Nakashima M, Vematsu J, Kosuge K, et al. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1995; 39 (1): 170-4
14. Child J, Mortiboy D, Andrews JM, et al. Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob Agents Chemother 1995; 39 (12): 2749-51
15. Montay G. Pharmacokinetics of sparfloxacin in healthy volunteers: a review. J Antimicrob Chemother 1996; 37 Suppl. A: 27-39
16. Hindler J. Tests to assess bactericidal activity. In: Isenberg HD, editor. Clinical microbiology procedures handbook. Washington DC: American Society for Microbiology, 1992: 5.16.14-21
17. Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother 1993; 37 (2): 349-53
18. Child J, Andrews J, Boswell F, et al. The in vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother 1995; 35 (6): 869-76
19. Zhang YY, Wang F, Zhang J, et al. In vitro antibacterial activity of levofloxacin. Drugs 1995; 49 Suppl. 2: 274-5
20. Paradelis AG, Delidou K, Grigoriadou A, et al. The antimicrobial activity of sparfloxacin, a new quinolone. Drugs 1995; 49 Suppl. 2: 238-9